BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
$9,88
Preço · Ago 18, 2026
Fundamentais a partir de Ago 5, 2026
Intervalo 52 Semanas
$6–$11
74% of range
Classificação do Analista
BUY
17 analysts
Preço-Alvo
$21
+111% upside
P/E (TTM)
9.7
ROE
-97.6%
Margem de Lucro Líquido
30.2%
Sobre BioCryst Pharmaceuticals, Inc. - Common Stock Visão geral da empresa da Wikipedia
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
Ler mais
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
BCRX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$9.88
Capitalização de Mercado
$2.51B
P/E (TTM)
9.7
EPS (TTM)
$1.21
Receita (TTM)
$875M
Rendimento div.
—
ROE
-97.6%
Dívida/Capital
0.0
Intervalo 52 Semanas
$6 – $11
BCRX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$875M
2016-12-31
→
2025-12-31
EPS
$1.21
2020-12-31
→
2025-12-31
Fluxo de caixa livre
$345M
2016-12-31
→
2025-12-31
Margens
30.2%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
BCRX
Mediana de Pares
P/E (TTM)
9.7
97.6
P/S (TTM)
2.9
7.7
P/B
-21.1
8.0
EV / EBITDA
6.5
—
Price / FCF (Preço / FCF)
7.3
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
BCRX
Mediana de Pares
Operating Margin (Margem Operacional)
39.0%
—
Net Profit Margin (Margem de Lucro Líquido)
30.2%
-51.7%
ROA
52.5%
-44.2%
ROE
-97.6%
-63.5%
ROIC
-282.4%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
BCRX
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
0.0
18.7
Current Ratio (Índice de liquidez corrente)
2.1
4.9
Quick Ratio (Índice de Liquidez Seca)
1.9
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
BCRX
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
94.1%
—
Revenue CAGR 3Y (CAGR Receita 3A)
47.8%
—
Revenue CAGR 5Y (CAGR Receita 5A)
117.9%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
BCRX
Mediana de Pares
BCRX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
17 analistas
- Compra forte 5 29,4%
- Compra 10 58,8%
- Manter 2 11,8%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
11 analistas · 2026-08-17
Mediana
$17.00
Média
$20.82
← Abaixo de todos os alvos
$9.88
Mín
$12.00
Máx
$32.00
Alvo mediano
$17.00
+72,1%
Alvo médio
$20.82
+110,7%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.02%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.30 | $0.12 | 0.18% |
| 31 de Março de 2026 | $-0.09 | $0.05 | -0.14% |
| 31 de Dezembro de 2025 | $0.01 | $0.04 | -0.03% |
| 30 de Setembro de 2025 | $0.06 | $0.04 | 0.02% |
| 30 de Junho de 2025 | $0.04 | $0.01 | 0.03% |
| 31 de Março de 2025 | $0.00 | $-0.07 | 0.07% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Balanço Patrimonial 27
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Liquidez e Solvência 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 13
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | -418,684,000 | 210,176,000 | 209,519,000 | 208,882,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | -436,451,000 | 219,885,000 | 219,886,000 | 215,261,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Balanço Patrimonial 24
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Fluxo de Caixa 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Avaliação (TTM) 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $697M | $625M | · | $585M | $535M | $465M | · | $406M | $371M | $331M | · | $314M | $293M | $260M | · | $232M | |
| Net Income TTM | $-625M | $-704M | · | $4M | $-22M | $-62M | · | $-98M | $-160M | $-200M | · | $-207M | $-230M | $-229M | · | $-234M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -3.8 | -3.3 | · | 759.0 | -81.5 | -25.0 | · | -15.5 | -7.5 | -4.9 | · | -6.4 | -5.7 | -6.8 | · | -9.8 | |
| P/S | 3.7 | 3.9 | · | 2.7 | 3.5 | 3.4 | · | 3.9 | 3.4 | 3.2 | · | 4.3 | 4.6 | 6.1 | · | 10.1 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| P / FCF | · | -38.9 | · | · | · | -56.7 | · | · | · | -19.4 | · | · | · | -33.0 | · | · | |
| EV / EBITDA | 26.4 | -3.7 | · | 53.4 | 62.6 | 73.7 | · | 232.9 | 172.6 | -89.7 | · | -125.1 | -71.5 | -59.0 | · | -133.3 | |
| EV / FCF | · | -41.4 | · | · | · | -57.5 | · | · | · | -23.6 | · | · | · | -34.7 | · | · | |
| EV / Revenue | 3.7 | 4.1 | · | 2.7 | 3.5 | 3.4 | · | 4.4 | 4.1 | 3.8 | · | 4.8 | 5.1 | 6.4 | · | 10.0 | |
| Earnings Yield | -26.0% | -30.5% | · | 0.13% | -1.2% | -4.0% | · | -6.5% | -13.3% | -20.5% | · | -15.5% | -17.5% | -14.8% | · | -10.2% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $875M | $451M | $331M | $271M | $157M |
| Margem Operacional % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Lucro líquido | $264M | $-89M | $-227M | $-247M | $-184M |
| EPS Diluído | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Índice de liquidez corrente | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Índice de Liquidez Seca | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $345M | $-53M | $-97M | $-163M | $-145M |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 346 declarantes · $2.1B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 63 (-7 vs trimestre anterior) | 34 (-7 vs trimestre anterior) | 130 (+19 vs trimestre anterior) | 83 (+3 vs trimestre anterior) | +25.9M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 7,51% | Ações |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 7,21% | Ações |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 7,16% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 5,39% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 5,29% | Ações |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 5,23% | Ações |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 4,89% | Ações |
| JANUS HENDERSON GROUP PLC | $83.961.589 | 8.814.865 | 3,98% | Ações |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 3,94% | Ações |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 3,21% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $53.581.572 | 5.356.880 | 2,54% | Ações |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 2,52% | Ações |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,90% | Ações |
| GOLDMAN SACHS GROUP INC | $35.393.210 | 3.539.321 | 1,68% | Ações |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,61% | Ações |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,51% | Ações |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,37% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $27.161.110 | 2.716.111 | 1,29% | Ações |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 1,24% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 1,20% | Ações |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 1,20% | Ações |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 1,19% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 1,12% | Ações |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 1,11% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $21.850.110 | 2.185.011 | 1,04% | Ações |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,90% | Ações |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,89% | Ações |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,88% | Ações |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,88% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,83% | Ações |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,83% | Ações |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,78% | Ações |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,77% | Ações |
| JANE STREET GROUP, LLC | $14.267.680 | 1.426.768 | 0,68% | Ações |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,64% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,57% | Ações |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,57% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,56% | Ações |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,53% | Ações |
| JANE STREET GROUP, LLC | $9.944.130 | 994.413 | 0,47% | Opção de compra |
| Cubist Systematic Strategies, LLC | $9.462.419 | 1.246.696 | 0,45% | Ações |
| MOORE CAPITAL MANAGEMENT, LP | $8.483.360 | 848.336 | 0,40% | Ações |
| FMR LLC | $8.062.330 | 806.233 | 0,38% | Ações |
| BANK OF AMERICA CORP /DE/ | $7.754.020 | 775.402 | 0,37% | Ações |
| ExodusPoint Capital Management, LP | $7.449.170 | 744.917 | 0,35% | Ações |
| Man Group plc | $7.324.800 | 732.480 | 0,35% | Ações |
| Rosalind Advisors, Inc. | $7.215.040 | 721.504 | 0,34% | Ações |
| Schonfeld Strategic Advisors LLC | $7.108.160 | 710.816 | 0,34% | Ações |
| BlackRock, Inc. | $5.984.400 | 598.440 | 0,28% | Ações |
| Elmind Capital, LP | $5.200.000 | 520.000 | 0,25% | Ações |
| Bridgewater Associates, LP | $4.910.570 | 491.057 | 0,23% | Ações |
| NAN FUNG TRINITY (HK) LTD | $4.500.000 | 450.000 | 0,21% | Ações |
| SPHERA FUNDS MANAGEMENT LTD. | $4.220.510 | 422.051 | 0,20% | Ações |
| Swiss National Bank | $4.152.680 | 415.268 | 0,20% | Ações |
| Susquehanna Portfolio Strategies, LLC | $4.047.040 | 404.704 | 0,19% | Ações |
| DAFNA Capital Management LLC | $4.002.480 | 400.248 | 0,19% | Ações |
| Hudson Bay Capital Management LP | $4.000.000 | 400.000 | 0,19% | Ações |
| Aquatic Capital Management LLC | $3.628.950 | 362.895 | 0,17% | Ações |
| DOLIVER CAPITAL ADVISORS, INC. | $3.563.603 | 374.328 | 0,17% | Ações |
| Assenagon Asset Management S.A. | $3.530.440 | 353.044 | 0,17% | Ações |
| Kodai Capital Management LP | $3.515.993 | 468.799 | 0,17% | Ações |
| MACKENZIE FINANCIAL CORP | $3.472.990 | 347.299 | 0,16% | Ações |
| CITIGROUP INC | $3.467.520 | 346.752 | 0,16% | Ações |
| Phocas Financial Corp. | $3.405.410 | 340.541 | 0,16% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.238.000 | 323.800 | 0,15% | Opção de compra |
| ALPS ADVISORS INC | $3.179.600 | 317.960 | 0,15% | Ações |
| ALLIANCEBERNSTEIN L.P. | $3.121.694 | 327.909 | 0,15% | Ações |
| RHUMBLINE ADVISERS | $2.798.390 | 279.839 | 0,13% | Ações |
| Rafferty Asset Management, LLC | $2.656.180 | 265.618 | 0,13% | Ações |
| Point72 Asset Management, L.P. | $2.609.170 | 260.917 | 0,12% | Ações |
| Nuveen, LLC | $2.599.030 | 259.903 | 0,12% | Ações |
| NFJ INVESTMENT GROUP, LLC | $2.568.330 | 256.833 | 0,12% | Ações |
| Nebula Research & Development LLC | $2.567.121 | 286.509 | 0,12% | Ações |
| WINTON GROUP Ltd | $2.556.000 | 255.600 | 0,12% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.459.444 | 258.345 | 0,12% | Ações |
| MARTINGALE ASSET MANAGEMENT L P | $2.425.080 | 242.508 | 0,12% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $2.324.670 | 232.467 | 0,11% | Ações |
| CITADEL ADVISORS LLC | $2.322.000 | 232.200 | 0,11% | Opção de compra |
| IEQ CAPITAL, LLC | $2.274.210 | 227.421 | 0,11% | Ações |
| Bank of New York Mellon Corp | $2.251.670 | 225.167 | 0,11% | Ações |
| D. E. Shaw & Co., Inc. | $2.249.120 | 224.912 | 0,11% | Ações |
| JUPITER ASSET MANAGEMENT LTD | $2.221.030 | 222.103 | 0,11% | Ações |
| HUSSMAN STRATEGIC ADVISORS, INC. | $2.100.000 | 210.000 | 0,10% | Ações |
| PFM Health Sciences, LP | $2.073.570 | 207.357 | 0,10% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $1.962.800 | 196.280 | 0,09% | Ações |
| TUDOR INVESTMENT CORP ET AL | $1.951.280 | 195.128 | 0,09% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.853.000 | 185.300 | 0,09% | Opção de venda |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $1.820.161 | 233.354 | 0,09% | Ações |
| Engineers Gate Manager LP | $1.750.020 | 175.002 | 0,08% | Ações |
| Squarepoint Ops LLC | $1.747.140 | 174.714 | 0,08% | Ações |
| QTR Family Wealth, LLC | $1.610.820 | 161.082 | 0,08% | Ações |
| Gotham Asset Management, LLC | $1.564.210 | 156.421 | 0,07% | Ações |
| CITADEL ADVISORS LLC | $1.450.000 | 145.000 | 0,07% | Opção de venda |
| Corient Private Wealth LP | $1.429.860 | 142.986 | 0,07% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $1.386.570 | 138.657 | 0,07% | Ações |
| Quantinno Capital Management LP | $1.374.530 | 137.453 | 0,07% | Ações |
| MetLife Investment Management, LLC | $1.356.700 | 135.670 | 0,06% | Ações |
| PROFUND ADVISORS LLC | $1.340.340 | 134.034 | 0,06% | Ações |
| Virtus Investment Advisers, LLC | $1.336.640 | 133.664 | 0,06% | Ações |
| ADAR1 Capital Management, LLC | $1.330.000 | 133.000 | 0,06% | Ações |
Executivos da empresa 51 insiders · 21 diretores · 30 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 de Dezembro de 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 de Dezembro de 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 de Fevereiro de 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 de Março de 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 de Dezembro de 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 de Março de 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 de Maio de 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 6 de Abril de 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 de Março de 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 de Dezembro de 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 de Novembro de 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 de Março de 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 de Dezembro de 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 de Janeiro de 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 de Março de 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 de Fevereiro de 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 de Março de 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 de Julho de 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 de Julho de 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 de Julho de 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 de Maio de 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Conselheiro | 11 de Junho de 2026 A | 47.177 | 0 | 1 | $-100.285 |
| Theresa Heggie | Conselheiro | 11 de Junho de 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Conselheiro | 11 de Junho de 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Jill C. Milne | Conselheiro | 11 de Junho de 2026 A | 31.938 | 0 | 0 | $0 |
| Steven Frank | Conselheiro | 11 de Junho de 2026 A | 35.459 | 0 | 0 | $0 |
| Steven K Galson | Conselheiro | 11 de Junho de 2026 A | 27.794 | 0 | 0 | $0 |
| Jon P Stonehouse | Conselheiro | 11 de Junho de 2026 A | 1.339.775 | 0 | 0 | $0 |
| Vincent Milano | Conselheiro | 11 de Junho de 2026 A | 108.483 | 0 | 0 | $0 |
| Alan G Levin | Conselheiro | 11 de Junho de 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Conselheiro | 12 de Junho de 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Conselheiro | 12 de Junho de 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Conselheiro | 12 de Junho de 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Conselheiro | 13 de Junho de 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Conselheiro | 28 de Fevereiro de 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Conselheiro | 28 de Novembro de 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Conselheiro | 20 de Junho de 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Conselheiro | 24 de Maio de 2017 A | — | 0 | 0 | $0 |
| Charles A Sanders | Conselheiro | 29 de Fevereiro de 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Conselheiro | 2 de Maio de 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Conselheiro | 23 de Maio de 2012 A | — | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Conselheiro | 23 de Maio de 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Conselheiro | 12 de Maio de 2011 A | — | 0 | 0 | $0 |
| Beth C Seidenberg | Conselheiro | 13 de Maio de 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Conselheiro | 13 de Maio de 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Conselheiro | 16 de Maio de 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Conselheiro | 16 de Maio de 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Conselheiro | 18 de Março de 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Conselheiro | 17 de Maio de 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Conselheiro | 4 de Novembro de 2003 M | 46.785 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 15 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 declarações | 31 de Julho de 2018 | — | Declaração inicial | — | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 de Abril de 2018 | — | Declaração inicial | Investimento passivo | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 declarações | 16 de Agosto de 2016 | — | Declaração inicial | — | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 declarações | 23 de Outubro de 2012 | — | Declaração inicial | — | SEC |
| Julian C. Baker, Felix J. Baker ×4 declarações | 13 de Outubro de 2011 | — | Declaração inicial | — | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 declarações | 20 de Agosto de 2007 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 7 de Dezembro de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 7 de Dezembro de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 7 de Dezembro de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada | 13 de Outubro de 2005 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 26 de Fevereiro de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 25 de Fevereiro de 2004 | — | Declaração inicial | — | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 24 de Fevereiro de 2004 | — | Declaração inicial | — | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 declarações | 31 de Outubro de 2003 | — | Declaração inicial | — | SEC |
| William W. Featheringill | 14 de Fevereiro de 2002 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 53 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,65% | 1.023.838 SH | 8 de Agosto de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,93% | 125.015 NS | 30 de Abril de 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 1,26% | 1.682 NS | 30 de Abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,67% | 381.305 NS | 30 de Abril de 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,54% | 612.341 NS | 30 de Abril de 2026 | N-PORT |
| CALF · Pacer Funds Trust | 0,41% | 1.556.494 NS | 30 de Abril de 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,28% | 364.624 NS | 30 de Abril de 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0,25% | 59.894 NS | 31 de Maio de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,24% | 72.535 SH | 8 de Agosto de 2026 | Diário |
| GSSC · Goldman Sachs ETF Trust | 0,19% | 213.133 NS | 31 de Maio de 2026 | N-PORT |
| SMLF · iShares Trust | 0,17% | 758.958 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,16% | 13.830 SH | 8 de Agosto de 2026 | Diário |
| IBB · iShares Trust | 0,15% | 1.580.105 SH | 8 de Agosto de 2026 | Diário |
| ESSC · Strategy Shares | 0,15% | 4.183 NS | 30 de Abril de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 8 de Agosto de 2026 | Diário |
| IWO · iShares Trust | 0,13% | 2.097.061 SH | 8 de Agosto de 2026 | Diário |
| BIB · ProShares Trust | 0,11% | 9.271 NS | 31 de Maio de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 57.134 NS | 30 de Abril de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 81.871 NS | 30 de Abril de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 8 de Agosto de 2026 | Diário |
| ISCG · iShares Trust | 0,07% | 73.787 SH | 8 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,07% | 5.925.076 SH | 8 de Agosto de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 206.325 SH | 8 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,06% | 97.958 NS | 30 de Abril de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 806.097 NS | 30 de Abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,05% | 10.652 NS | 31 de Maio de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,05% | 1.154.262 NS | 31 de Maio de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,03% | 10.494 SH | 8 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 96.151 NS | 30 de Abril de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 8 de Agosto de 2026 | Diário |
| UWM · ProShares Trust | 0,03% | 8.331 NS | 31 de Maio de 2026 | N-PORT |
| URTY · ProShares Trust | 0,02% | 8.425 NS | 31 de Maio de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 8 de Agosto de 2026 | Diário |
| WSML · iShares Trust | 0,02% | 11.689 SH | 8 de Agosto de 2026 | Diário |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 9.529 NS | 31 de Maio de 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 212 NS | 31 de Maio de 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 80.493 NS | 31 de Maio de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 74.317 NS | 30 de Abril de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 72.218 SH | 8 de Agosto de 2026 | Diário |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,00% | 937 NS | 31 de Maio de 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 336.352 SH | 8 de Agosto de 2026 | Diário |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 141.645 NS | 31 de Maio de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 6.314 NS | 30 de Abril de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 34.873 NS | 30 de Abril de 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,00% | 8.956 NS | 30 de Abril de 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0,00% | 129 NS | 31 de Maio de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 3.019 NS | 30 de Abril de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 8 de Agosto de 2026 | Diário |